Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Tackle Zero Based Budgeting And Child Expenses with methods that allocate funds for loved ones without compromising long-term goals.
28,655 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
When you weigh broad health exposure against a focused pharmaceutical bet, two ETFs stand out: IYH and PJP. This guid...
When a quarterly miss hits the wires, investors scramble to interpret the fallout. This deep dive explains why calume...
AI markets are crowded with flashy names, but the real backbone often lies in the companies that enable AI at scale. ...
Long-term investors chase multibagger dreams. This article explores a high-potential biotech setup with 26 late-stage...
Symbotic's shiny narrative has investors buzzing, but the biggest gains often hinge on real execution, not just optim...
A fast IPO run can leave investors excited but unsure what comes next. We break down whether this stock soared 123% s...
AI-driven capital spending and the wealth boost from tech stocks are accelerating U.S. GDP growth. Analysts say the d...
Retail traders flock to energy names, lifting broad ETFs even as oil prices warn of a choppier path. This report trac...
A Federal Reserve survey finds tariffs hit small firms' costs, forcing price hikes and hiring shifts as the burden sp...
A coalition of Democratic attorneys general filed lawsuits seeking refunds on tariffs imposed under a new Section 122...
A federal judge in San Jose blocked an attempt to sever the CFPB's funding from the Federal Reserve, keeping the bure...